NEW YORK (GenomeWeb) – Oxford Cancer Biomarkers (OCB) announced today that it has licensed its suite of in vitro colorectal cancer diagnostics to Chinese precision medicine firm My-BioMed Biotechnology (MBM).

Under the terms of the deal, MBM will have access to OCB's ColoTox, ColoProg, and ColoPredict tests and technologies, which will be offered in China through a purpose-built biomedical laboratory. Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.